Synthetic Nanovaccines Against Respiratory Pathogens (SYNARP). Addendum
Final addendum rept. 1 Jul 2009-30 Jun 2014
NEBRASKA UNIV MEDICAL CENTER OMAHA
Pagination or Media Count:
The overall goal of this proposal was to develop fully synthetic vaccines against respiratory infections using novel nanotechnology platforms based on safe and degradable adjuvant polymer systems that enhance antigen presentation and stimulate immunity. Three novel versatile technology platforms were evaluated a biodegradable polyanhydride nanospheres BPN carrying a polypeptideprotein antigen Platform A b polymeric micelles of Pluronic block copolymer as DNA vaccine adjuvant Platform B and c block ionomer complexes BIC for targeted delivery of DNA or protein antigen to the antigen presenting cells APCs Platform C. The central hypothesis was that these polymeric nanoscale delivery systems could provide versatile platforms for development of effective, safe, and cost-efficient vaccines. The materials used in these platforms demonstrated immunomodulatory capabilities and can be targeted to specific populations of immune cells to elicit most efficient immune response. The proposal was focusing on achieving the following specific technical objectives 1 Develop molecular methods for intervention strategies employing novel synthetic nanovaccine platforms encapsulating DNA and proteinpeptide antigens that elicit immune response against influenza H5N1 2 Test the efficacy of nanovaccines-based intervention regimens against influenza H5N1 in animal models. The best technology or their combination will be determined for future development.
- Medicine and Medical Research